Abstracts

HepB-CpG Vaccine Is Superior to HepB-alum in People With HIV and Prior Vaccine Nonresponse: A5379

Background: Conventional Hepatitis B surface antigen (HBsAg)-based vaccines achieve seroprotection response (SPR, HBsAb≥10 mIU/mL) in 35-80% of people with HIV (PWH) with 3 doses. HepB-CpG (vaccine with a TLR-9 agonist adjuvant) achieves high SPR in PWH, but limited data exist for non-responders to conventional vaccines. Methods: ACTG A5379 is an ongoing, open-label study to evaluate…

ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART

Background: ODYSSEY demonstrated superior 96-week efficacy for dolutegravir(DTG)+2NRTIs versus standard-of-care (SOC, 77% efavirenz first-line, 96% boosted PI second-line) in children starting first-line (ODYSSEY A) or second-line ART (ODYSSEY B). During a further ~3 years’ extended follow-up in Africa and Thailand, children on SOC were switching to DTG following national guidelines. Here we present efficacy and…

Sex-Based Differences in HIV-1 Reservoir Profile in Individuals With Long-Term ART Suppression

Background: Women account for over half of people living with HIV (PLH) but they are largely underrepresented in HIV-1 cure studies. Biological sex impacts host immune responses which may lead to sex-specific selection and evolution of HIV reservoir cells. However, sex-specific differences in HIV reservoir landscapes, including proviral reservoir size, composition, and integration site profile…

Lung Function, HIV and Mortality: Analyses From the AIDS Linked to the Intravenous Experience Cohort

Background: Chronic lung disease is an increasingly important comorbidity for persons aging with HIV. Persons with HIV(PWH) can experience accelerated decline in lung function, including spirometry measures(FEV1). The current implications of this lung function decline on all cause and HIV-related mortality warrants further investigation. Additionally, the normalized FEV1Q has recently been developed to improve interpretation…

COVID Incidence and Severity in Persons With Reinfection vs Post-Vaccination Breakthrough Infection

Background: COVID-19 vaccine effectiveness wanes over time. Natural infection also provides a high level of protection from reinfection and from severe, critical, or fatal disease. While both natural and vaccine induced immunity are highly protective, reinfections after natural infection and breakthrough infections after vaccination have been reported. Our aim was to determine the incidence rate…

Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial

Background: Broadly neutralizing antibodies (bNAbs) hold promise for antiretroviral therapy (ART). ACTG A5357 is a phase II, single-arm clinical trial, investigating the combination of VRC07-523LS, a bNAb targeting the HIV-1 CD4-binding site, and long-acting cabotegravir (LA CAB) for maintenance ART Methods: Participants are adults with HIV, virally suppressed for >2 years, a current CD4 count…

Lenacapavir Plus bNAbs for People With HIV and Sensitivity to Either Teropavimab or Zinlirvimab

Background: Lenacapavir (LEN) is a first-in-class, long-acting HIV-1 capsid inhibitor approved for treatment of HIV-1 infection in adults with multidrug resistance. Teropavimab (TAB) & zinlirvimab (ZAB) are long-acting broadly neutralizing antibodies (bNAbs), targeting the CD4-binding site & V3 loop of gp120, respectively. In a phase 1b study (NCT04811040), LEN+TAB+ZAB maintained virologic suppression (VS) for 6…

Randomized Trial of Cabotegravir and Rilpivirine Long-Acting in Africa (CARES): Week 48 Results

Background: Long-acting injectable therapy (LA) is a recommended option for individualized treatment of human immunodeficiency virus type 1 (HIV-1) infection in resource-rich settings. Additional evidence is required to determine the role of LA for treatment programs in Africa, where demographic factors, viral subtypes, prior treatment exposure, prevalence of pre-existing antiviral drug resistance and standardized approach…